Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), and Exothera S.A., a full-service CDMO specialized in gene therapy, vaccines, and oncolytic viruses, entered a collaboration agreement to demonstrate the industrialization potential of Remedium’s AAV2-FGF18. Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18, according to the company. Remedium’s ...